Another dengue vaccine candidate, Takeda (TAK-003), which uses a live attenuated strain of DENV-2 with PrM and E of different serotypes, elicits a robust humoral response along with the generation of polyfunctional CD8+ T cell response (15), which is serotype cross-reactive. The gene discussed is CD8A; the disease is dengue disease.